Experimental therapeutic approaches include ex vivo gene therapy to correct LAMB3 and COL7A1 mutations in epidermal stem cells (10, 11), cell therapies for dystrophic EB, repurposed drugs with anti-inflammatory effects for dystrophic EB and EB simplex and topical agents aiming at improving wound healing. Here, COL7A1 is linked to epidermolysis bullosa.